Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently published results of trials on elderly patients with malignant gliomas have revived the call for routine MGMT testing for clinical decision making.
|
23083460 |
2013 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
|
16033832 |
2005 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The DNA repair enzyme O(6)-methylguanine DNA methyltransferase (MGMT) may cause resistance to DNA-alkylating drugs commonly used in the treatment of anaplastic oligodendrogliomas and other malignant gliomas.
|
15455350 |
2005 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
|
19901110 |
2009 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
|
27158275 |
2016 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Currently, the most efficacious treatment for malignant gliomas is temozolomide; however, gliomas expressing the DNA repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) are resistant to this drug.
|
18089777 |
2007 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study identified clinicopathological factors related to postoperative seizure in HGGs and found two predictive biomarkers of postoperative seizure: MGMT and EGFR.
|
26808114 |
2016 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
|
16899598 |
2006 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
According to pathological examination, the tumor was a high-grade glioma that was positive for methylated O-6-methylguanine-DNA methyltransferase promoter.
|
20354758 |
2010 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results.
|
29882028 |
2018 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation in malignant gliomas.
|
20725792 |
2010 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is a predictive parameter for the response of malignant gliomas to alkylating agents such as temozolomide.
|
22614944 |
2012 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
|
19997073 |
2010 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the clinical therapeutic efficacy of TMZ might be improved by a combination with IFN-beta in malignant gliomas unmethylated at the MGMT gene.
|
19513561 |
2009 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant methylation of the MGMT (O6-methylguanine-DNA methyltransferase) DNA-repair gene is a predictive marker for the response to chemotherapy with alkylating agents (e.g., temozolomide) in malignant gliomas.
|
18795231 |
2009 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The MGMT promoter methylation status of malignant gliomas can be reliably determined from small-sized stereotactic biopsies.
|
17691113 |
2007 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
LOH of 1p in the heterogeneous population of malignant gliomas may be one of the important factors besides MGMT methylation that predict better outcome in patients treated with TMZ.
|
17721049 |
2007 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We investigated the impact of MGMT methylation and expression on survival of children with high-grade glioma (HGG) registered into the German HIT-GBM database receiving temozolomide (TMZ) as part of their treatment (n = 21 relapsed, n = 4 primary).
|
19856394 |
2010 |
Malignant Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
|
25111384 |
2014 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
|
21365007 |
2011 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) removes mutagenic adducts from the O6 position of guanine, thereby protecting the genome against guanine : cytosine to adenine : thymine transition and, meanwhile, conferring tumor resistance to many anti-cancer alkylating agents commonly used in the treatment of malignant gliomas.
|
14570288 |
2003 |
Malignant Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Resistance of malignant gliomas to TMZ can be overcome by synchronizing metronomic TMZ regimen with MGMT expression.
|
21892781 |
2012 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Logistic regression analysis showed that Leu84Phe of MGMT gene and pathological grade were independent risk factors for the increase of TMZ resistance in patients with malignant gliomas.
|
28409559 |
2017 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon alpha and beta (IFNA, IFNB) genes and lack of O6-methylguanine-DNA methyltransferase (MGMT) expression.
|
1501894 |
1992 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To determine the prognostic value of isocitrate dehydrogenase 1 (IDH1) mutation, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and 1p/19q co-deletion in Japanese patients with malignant gliomas.
|
24160898 |
2013 |